Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Pharmacological Characterization of Human m1 Muscarinic Acetylcholine Receptors with Double Mutations at the Junction of TM VI and the Third Extracellular Domain

X.-P. Huang, F. E. Williams, S. M. Peseckis and W. S. Messer Jr.
Journal of Pharmacology and Experimental Therapeutics September 1998, 286 (3) 1129-1139;
X.-P. Huang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. E. Williams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. M. Peseckis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. S. Messer Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

A mutant human m5 receptor containing the mutations of Ser465 to Tyr and Thr466 to Pro showed constitutive activity. By replacing the equivalent Ser388 with Tyr and Thr389 with Pro, we created a mutant human m1 (Hm1) receptor with comparable double mutations. The mutant receptor, Hm1(Ser388Tyr, Thr389Pro), was stably expressed in A9 L cells and displayed enhanced responses to classical muscarinic agonists with significantly increased potencies. Choline, a normal component of growth media, showed an efficacy comparable to acetylcholine and carbachol at Hm1(Ser388Tyr, Thr389Pro) receptors. Methylcarbachol, a selective nicotinic agonist, exhibited partial agonist activity at human m1 wild-type receptors and full agonist activity at Hm1(Ser388Tyr, Thr389Pro) receptors. l-Hyoscyamine inhibited the activities of choline and methylcarbachol. Muscarinic antagonists displayed small reductions in binding affinities, although muscarinic agonists showed greatly increased binding affinities for Hm1(Ser388Tyr, Thr389Pro) receptors. All agonists, including choline and methylcarbachol, showed multiple affinity states at Hm1(Ser388Tyr, Thr389Pro) receptors in the absence of GppNHp. The high affinity binding sites for acetylcholine, arecoline and choline were shifted in the presence of GppNHp. These results suggest that Hm1(Ser388Tyr, Thr389Pro) is conformationally favorable for agonist binding and receptor activation.

Footnotes

  • Send reprint requests to: Dr. W. S. Messer, Jr., Center for Drug Design and Development, Department of Medicinal and Biological Chemistry, College of Pharmacy, The University of Toledo, 2801 W. Bancroft St., Toledo, OH 43606-3390.

  • ↵1 This work was supported by NS 01493, NS 31173 and NS 35127.

  • Abbreviations:
    ACh
    acetylcholine
    APE
    arecaidine propargyl ester hydrobromide, DMEM, Dulbecco’s Modified Eagle Media
    FBS
    fetal bovine serum
    GppNHp
    guanylylimidodiphosphate
    Hm1
    human muscarinic acetylcholine receptor subtype 1
    Hm1(Ser388Tyr
    Thr389Pro), Hm1 mutant receptor with the mutations of Ser388 to Tyr and Thr389 to Pro
    Hm5
    human muscarinic acetylcholine receptor subtype 5
    IP
    inositol phosphate
    KH buffer
    Krebs-Henseleit buffer, mAChR, muscarinic acetylcholine receptor
    (R)-QNB
    (R)-3-quinuclidinyl benzilate
    Ne3
    N-terminal region of the third extracellular domain
    TCA
    trichloroacetic acid, TM, transmembrane domain
    WT
    wild-type
    KSHV-GPCR
    G-protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus
    • Received February 5, 1998.
    • Accepted May 13, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 286, Issue 3
1 Sep 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological Characterization of Human m1 Muscarinic Acetylcholine Receptors with Double Mutations at the Junction of TM VI and the Third Extracellular Domain
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Pharmacological Characterization of Human m1 Muscarinic Acetylcholine Receptors with Double Mutations at the Junction of TM VI and the Third Extracellular Domain

X.-P. Huang, F. E. Williams, S. M. Peseckis and W. S. Messer
Journal of Pharmacology and Experimental Therapeutics September 1, 1998, 286 (3) 1129-1139;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Pharmacological Characterization of Human m1 Muscarinic Acetylcholine Receptors with Double Mutations at the Junction of TM VI and the Third Extracellular Domain

X.-P. Huang, F. E. Williams, S. M. Peseckis and W. S. Messer
Journal of Pharmacology and Experimental Therapeutics September 1, 1998, 286 (3) 1129-1139;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Is Hydroxylamine-Induced Cytotoxicity a Valid Marker for Hypersensitivity Reactions to Sulfamethoxazole in Human Immunodeficiency Virus-Infected Individuals?
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics